Importance of Powder Residence Time for the Aerosol Delivery Performance of a Commercial Dry Powder Inhaler Aerolizer®

2012 ◽  
Vol 25 (5) ◽  
pp. 265-279 ◽  
Author(s):  
Liqun Jiang ◽  
Yue Tang ◽  
Hongjiu Zhang ◽  
Xifeng Lu ◽  
Xijing Chen ◽  
...  
Keyword(s):  
Residence Time ◽  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder ◽  
Delivery Performance

Influence of Mouthpiece Geometry on the Aerosol Delivery Performance of a Dry Powder Inhaler

2007 ◽  
Vol 24 (8) ◽  
pp. 1450-1456 ◽  
Author(s):  
Matthew S. Coates ◽  
Hak-Kim Chan ◽  
David F. Fletcher ◽  
Herbert Chiou
Keyword(s):  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder ◽  
Delivery Performance

Drug Delivery Performance of the Mometasone Furoate Dry Powder Inhaler

2001 ◽  
Vol 14 (4) ◽  
pp. 487-494 ◽  
Author(s):  
T.T. Yang ◽  
S. Li ◽  
B. Wyka ◽  
D. Kenyon
Keyword(s):  
Drug Delivery ◽  
Dry Powder Inhaler ◽  
Mometasone Furoate ◽  
Dry Powder ◽  
Delivery Performance

scholarly journals The Acoustic Features of Inhalation can be Used to Quantify Aerosol Delivery from a Diskus™ Dry Powder Inhaler

2014 ◽  
Vol 31 (10) ◽  
pp. 2735-2747 ◽  
Author(s):  
Jansen N. Seheult ◽  
Peter O’Connell ◽  
Kee Chun Tee ◽  
Tariq Bholah ◽  
Hasan Al Bannai ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Acoustic Features ◽  
Aerosol Delivery ◽  
Dry Powder

scholarly journals Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler

2015 ◽  
Vol 28 (3) ◽  
pp. 189-201 ◽  
Author(s):  
P. Worth Longest ◽  
Laleh Golshahi ◽  
Srinivas R.B. Behara ◽  
Geng Tian ◽  
Dale R. Farkas ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder

Quantifying Uncertainty in the Residence Time of the Drug and Carrier Particles in a Dry Powder Inhaler

2021 ◽  
Author(s):  
Antara Badhan ◽  
V M KRUSHNARAO Kotteda ◽  
Samia Afrin ◽  
Vinod Kumar
Keyword(s):  
Residence Time ◽  
Particle Density ◽  
Dry Powder Inhaler ◽  
Department Of Energy ◽  
Dry Powder ◽  
Throat Region ◽  
Particle In Cell ◽  
Pharmaceutical Ingredients ◽  
Fluidizing Agent ◽  
The Individual

Abstract Dry powder inhalers, used as a means for pulmonary drug delivery, typically contain a combination of active pharmaceutical ingredients (API) and significantly larger carrier particles. The micro-sized drug particles - which have a strong propensity to aggregate and poor aerosolization performance - are mixed with significantly large carrier particles that cannot penetrate the mouth-throat region to deagglomerate and entrain the smaller API particles in the inhaled airflow. Therefore, a DPI's performance depends on the carrier-API combination particles' entrainment and the time and thoroughness of the individual API particles' deagglomeration from the carrier particles. Since DPI particle transport is significantly affected by particle-particle interactions, particle sizes and shapes present significant challenges to CFD modelers to model regional lung deposition from a DPI. We employed the Particle-In-Cell method for studying the transport/deposition and the agglomeration and deagglomeration for DPI carrier and API particles in the present work. The proposed development will leverage CFD-PIC and sensitivity analysis capabilities from the Department of Energy laboratories: Multiphase Flow Interface Flow Exchange and Dakota UQ software. A data-driven framework is used to obtain the reliable low order statics of the particle's residence time in the inhaler. The framework is further used to study the effect of drug particle density, carrier particle density and size, fluidizing agent density and velocity, and some numerical parameters on the particles' residence time in the inhaler.

AEROSOL DELIVERY FROM AN ACTIVE EMISSION MULTI-SINGLE DOSE DRY POWDER INHALER

1997 ◽  
Vol 15 (1) ◽  
pp. 51-63 ◽  
Author(s):  
N. M. CONCESSIO ◽  
R. JÄGER-WALDAU ◽  
A. J. HICKEY
Keyword(s):  
Single Dose ◽  
Dry Powder Inhaler ◽  
Aerosol Delivery ◽  
Dry Powder
Sign in / Sign up

Export Citation Format

Share Document